Analysis of drug targets and key pharmaceutical companies in pain therapeutic area, are you ready?

• Potential innovative targets for new pain drugs
• Breakthroughs and innovations of non-addictive pain drugs
• Competition landscape of the top 10 domestic companies in pain therapeutic area
• An innovative biotech roadshow

Event details

DATE Thursday, Nov 14, 2024 VENUE Online Webex / Zoom TIME 10:00 – 11:00 Berlin time (CET) 16:00 – 17:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Nov 14, 2024

PRESENTERS Lingling Cao, CEO & Founder Zhang Ran, Medical advisor REGISTER +86 21 5386 3003 BD@lingmed.net

Agenda

CET 10:00 - 10:30	Analysis of drug targets and key pharmaceutical companies in pain therapeutic area	by Zhang Ran  (Chinese)
CET 10:30 - 10:35	Linkedbio services & projects introduction	by Lingling Cao  (English)
CET 10:35 - 10:55	An innovative biotech roadshow	by Guest speaker   (English)
CET 10:55 – 11:00	Q&A	(English & Chinese)

Presenters

Zhang Ran Medical advisor China Pharmaceutical University master HealthShare Management and Consulting Co., Ltd Co-founder 20 years of experience in new drug development. Engaged in new drug research and development in Yangtze River Pharmaceutical Group、Beijing Kawin Technology Share-Holding Co., Ltd.、Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. Co-founded HealthShare in 2016. Serve a number of listed pharmaceutical enterprises. Mainly engaged in research and development pipeline strategic planning, new drug project evaluation, research and development management.

Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany